Startseite>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>3'-Hydroxypterostilbene

3'-Hydroxypterostilbene

Katalog-Nr.GC35112

3'-Hydroxypterostilben ist ein Pterostilben-Analogon. 3'-Hydroxypterostilben hemmt das Wachstum von COLO 205-, HCT-116- und HT-29-Zellen mit IC50-Werten von 9,0, 40,2 bzw. 70,9 μM. 3'-Hydroxypterostilben reguliert die PI3K/Akt- und MAPK-Signalwege signifikant herunter und hemmt wirksam das Wachstum menschlicher Dickdarmkrebszellen, indem es Apoptose und Autophagie induziert. 3'-Hydroxypterostilben kann fÜr die Krebsforschung verwendet werden.

Products are for research use only. Not for human use. We do not sell to patients.

3'-Hydroxypterostilbene Chemische Struktur

Cas No.: 475231-21-1

Größe Preis Lagerbestand Menge
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

3'-Hydroxypterostilbene, a natural pterostilbene analogue, effectively inhibits the growth of human colon cancer cells (IC50s of 9.0, 40.2, and 70.9 µM for COLO 205, HCT-116, and HT-29 cells, respectively) by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene inhibits the PI3K/Akt/mTOR/p70S6K, and p38MAPK pathways and activates the ERK1/2, JNK1/2 MAPK pathways[1]. Apoptosis[1]Autophagy[1]

[1]. Cheng TC, et al. Potent anti-cancer effect of 3'-hydroxypterostilbene in human colon xenograft tumors. PLoS One. 2014 Nov 12;9(11):e111814.

Bewertungen

Review for 3'-Hydroxypterostilbene

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 3'-Hydroxypterostilbene

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.